Retrospective Study Using Next Generation Sequencing (NGS) on Biological Samples to Improve Genetic Counseling for Patients With Previously Explored Craniofacial Midline Defects.

Holoprosencephaly Clinical Trial

— EXOMEDIANE  

Official title:

EXOMEDIANE - Retrospective Study Using High Throughput Sequencing (HTS) on Biological Samples to Improve Genetic Counseling for Patients With Previously Explored Craniofacial Midline Defects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04691414
• Other study ID #: 35RC20_8894_EXOMEDIANE
• Status: Completed
• Start date: February 10, 2021
• Est. completion date: December 6, 2021

Study information

• Verified date: December 2021
• Source: Rennes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Holoprosencephaly, or HPE, is the most common congenital cerebral malformation in humans and the most severe of a group of pathologies related to a deficiency of the SHH signalling pathway (Sonic Hedgehog SHH-D). It is characterized by severe cerebral and craniofacial abnormalities.

The regulation of SHH concentration is therefore crucial for correct craniofacial development.

Despite the recent identification of about 20 genes, 70% of cases of EHPE and craniofacial midline abnormalities of genetic origin do not have a molecular diagnosis. It is therefore important to continue the search for new candidate genes to improve the understanding of brain and facial development and to improve genetic counseling for these families.

The development of Next-Generation Sequencing (NGS) technologies opens up the possibility of studying the exome or even the genome in a single manipulation. The latter type of analysis is particularly well suited to the discovery of new genes and will therefore improve the care of patients and their families.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: December 6, 2021
• Est. primary completion date: December 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with Craniofacial Midline Facial Anomalies (CMFLA) collected for genetic analysis

• Patients and relatives for whom consent for research-related genetic testing is available. A "trio" - patient and both parents is required for analysis of variant segregation and determination of mode of transmission.

• For patients who are minors, parental authority(ies) who have given consent for research genetic testing.

• Affiliation to a social security scheme

• Patient and parents do not object to their participation in the research.

• In the case of a patient who has reached the age of majority since the initial consent was obtained, a patient who has given consent to proceed with genetic analyses for research purposes.

Exclusion Criteria:

• adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.

Related Conditions & MeSH terms

• Holoprosencephaly

Intervention

Genetic:
• NGS
next-generation sequencing on preexisting samples

Locations

Country	Name	City	State
France	CHU Rennes	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with an identified genetic abnormality	Number of patients with an identified genetic abnormality	6 months
Secondary	Number of new genes identified	Number of new genes identified, and possible recurrence of variants in one or more new genes of interest.	6 months
Secondary	Pathogenic variants	Percentage of pathogenic variants identified in genes of the SHH pathway	6 months
Secondary	Modes of transmission of pathogenic variants	Percentage of variants identified according to the different modes of transmission (de novo, autosomal dominant, X-linked, autosomal recessive, oligogenism)	6 months